# 

## First Quarter 2022 Financial and Operational Results

May 13, 2022

## Forward-looking Statement Disclaimer

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use such word as "will", "may", "potential", "believe", "expect", "continue", "anticipate" and other similar terminology. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the potential impact of the VITALIZE study and the anticipated date data from such study and from other ongoing studies of the Company are available, the Company's ability to advance its development strategy, the potential to expand the Company's pipeline through business development, the expected dosing timeline for the AVALON Phase 2B trial, the expected timing for data to be available from the Phase I clinical trial evaluating MVP-S and DPX-SurMAGE, the sufficiency of the Company's cash position, the upcoming milestones discussed in this release, and the prospects for its lead immunotherapy and its other pipeline of immunotherapy candidates. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful design and completion of clinical trials and the timely receipt of all regulatory approvals to commence, and then continue, clinical studies and trials and the receipt of all regulatory approvals to commercialize its products. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forwardlooking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, but are not limited to, those related to the Company's expected timeline associated with its cash runway; the Company's priorities with MVP-S and its DPX delivery platform, the potential for its delivery platform and the anticipated timing of enrollment and results for its clinical trial programs and studies as others risks detailed from time to the Company's ongoing quarterly and annual filings with Canadian securities regulators and the U.S. Securities and Exchange Commission. Investors. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV's continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.



## Agenda & Corporate Highlights

Andrew Hall, MSc Chief Executive Officer

## Agenda



Andrew Hall, MSc Chief Executive Officer

> Celgene MERCK



Jeremy Graff, Ph.D Chief Scientific Officer

**BIOTHERA** pharmaceuticals

Lille



Joy Bessenger SVP, Investor Relations and Corp. Strategy

### deCODE genetics



Brittany Davison, CPA, CA SVP, Finance

O Grant Thornton

Introduction Andrew Hall, CEO

**Corporate Highlights** Andrew Hall, CEO

**Clinical and Translational Highlights** Jeremy Graff, CSO

Financial Highlights Brittany Davidson, VP Finance

**Questions & Answers** 



4

## **Our Vision**

We are committed to creating a portfolio of immunotherapies, based on our novel immune-educating platform, that bridge the gap between effective cancer treatments and patients' quality of life.

## Our Focus in 2022

- 1. Accelerate MVP-S towards registration in DLBCL and Ovarian Cancer,
- 2. Enhance IMV's pipeline through business development,
- 3. Enrich understanding of the DPX mechanism of action and its differentiation from prior cancer vaccine efforts through foundational science and translational research.





## 1Q 2022 - Highlights

Clinical efficacy of MVP-S in advanced, metastatic bladder cancer was presented at the AACR annual meeting

First patients dosed in the VITALIZE DLBCL study and in the Phase 1 non-muscle invasive bladder cancer study. We continue to enroll more patients in the breast cancer study.

We are activating clinical sites for the Phase 2B AVALON trial in patients with platinumresistant ovarian cancer

We are advancing our business development initiatives to create a pipeline of DPX-based immunotherapies



## **Press Release**

Michael P. Bailey, President and Chief Executive Officer of AVEO Oncology

## IMV Inc. Names Michael P. Bailey Chairman of The Board

Mr. Bailey has more than 30 years of pharmaceutical industry experience, having been instrumental in the commercial planning and launch of several new medicines across multiple oncology indications.



### **Clinical & Translational Updates**

Jeremy Graff, PhD Chief Scientific Officer


## AACR Annual Meeting 2022 Showcasing the DPX Platform

### MVP-S MoA: NK Cells Promote Efficacy

- > NK cells are involved in promoting anti-tumor responses to DPX-peptide immunotherapy
  - PO.IM02.14: Immune Response to Therapies 2 / Immune Monitoring and Clinical Correlates


### MVP-S in Advanced, Metastatic Bladder Cancer

- Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer
  - > CT035: Immunotherapy Combination Strategies in Clinical Trials



## NK Cells Are Involved in Promoting Anti-tumor Responses to DPX-peptide Immunotherapy





- Preclinical studies suggest that immunization with DPX-peptide formulation enables tumor control even in the absence of T or B cell function. Responses to the DPX-peptide therapy are partially mediated by NK-perforin dependent mechanisms.
- Evaluation of tumor biopsies collected from subjects treated with MVP-S based therapy revealed increased expression of cytolytic NK markers and enhanced infiltration of resting NK cells in patients with favorable outcome.
- Results from clinical/translational studies and preclinical models suggest a distinct role for NK cells, in addition to the previously recognized role for T and B cells, in DPXmediated immunotherapeutic efficacy.

10

## MVP-S/ CPA in Combination With Pembrolizumab in Patients With Advanced, Metastatic Bladder Cancer




### Treatment was well-tolerated

- mostly Grade 1-2 injection site reactions
- no severe adverse events attributed to MVP-S

#### > Of the 17 treated patients, 5 showed response

- 2 Complete (CR), 3 Partial Responses (PR) per RECIST
- Responsive lesions lymph nodes as well as liver
- > CRs/PRs in patients with prior checkpoint inhibitors
- Survivin-specific T cells most evident in responders


### Best Response per RECIST v1.1 (n =13)



## Further clinical study for the combination of MVP-S, pembrolizumab and low-dose, intermittent CPA in advanced, metastatic bladder cancer is warranted



11



Study Day






#### **APRIL 8-13 • #AACR22**

### **Background:**

Baseline tumor: 16.95mm Target Lesion: Para-aortic LN Non-target Lesion: Para-aortic LN Prior Tx: 3 Last Tx: Atezo, 12 month SD



## Case Study 5 - 73 year old female (CR)



#### APRIL 8-13 • #AACR22

### Background:

Baseline tumor: 51.28 mm


Target Lesions:

Para-aortic LN

Supraclavicular LN

Prior Tx: 1

Last Tx: Pembro, 12 month PR



## Clinical and Translational Update Summary

VITALIZE (ph2 r DLBCL)- enrolled first patients, opening new countries and activating additional sites

- First results expected Q3, 2022
- AVALON (ph2 Ovarian)- site activation is ongoing, on-track for Q3 2022
  - First patient expected Q3, 2022

Bladder Cancer

> Advanced/ metastatic bladder cancer study design in development

### DPX-SurMAGE cohort 2 expected to start Q3-4/ 2022

> NMIBC- enrolled first patients on MVP-S cohort

### Breast Cancer Neoadjuvant study- enrolled half of the first cohort (MVP-S + letrozole)

> Targeting San Antonio Breast Cancer Symposium, December 2022 for presentation of early results

### Scientific Mechanism Studies

- > Natural Killer Cells are critical for DPX-mediated efficacy
- > Advances the understanding that DPX activates a comprehensive immune response



## Q1 2022 Financial Results

Brittany Davison, CPA, CA Sr. Vice President, Finance

## Q1 2022 Financial Results

#### (in Thousands of US Dollars)

	Q1 2022	Q1 2021	Change (\$)
Total income	24	69	(45)
Expenses			
Research and development	6,631	4,744	1,887
General and administrative	3,990	3,161	829
Government assistance	(378)	(1,234)	856
Accreted interest and valuation adjustments	304	355	(51)
Total expenses	10,547	7,026	3,521
Net loss and comprehensive loss	(10,253)	(6,957)	(3,566)
Basic and diluted loss per share	(0.13)	(0.10)	(0.03)



## Q1 2022 Financial Results

#### (in Thousands of US dollars)

	March 31, 2022	Dec. 31, 2021
Statements of financial position data:		
Cash and cash equivalents	28,689	38,616
Pro forma cash and cash equivalents**	38,689	38,616
Working capital	27,131	37,127
Total assets	40,833	50,121
Total liabilities	29,134	28,579
Total shareholder's equity	11,699	21,542

\*\* Includes remaining \$10 million from existing debt facility available upon meeting a pre-set clinical milestone which we are on track to meet in Q2 2022



## **Next Milestones & Conclusion**

Andrew Hall, MSc Chief Executive Officer

## IMV's Upcoming Clinical Milestones

Progra	am	H1 2022	H2 2022
S S	DLBCL (VITALIZE)		<b>Clinical update</b> First results on early patients
Maveropepimut-S	Bladder	KOL Advisory Board to inform trial design	
averop	Ovarian (AVALON)		Phase 2B trial initiation
Σ	Breast		<b>Clinical update</b> First results
MVP-S and DPX-SurMAGE	Bladder (NMIBC)		Preliminary data with MVP-S



## **Questions & Answers**

